KRISTI LEIGH FENTON AGACNP-BC
Prescription History 1497409403
Nurse Practitioner - Acute Care in San Luis Obispo, CA

NPI Status: Active since February 08, 2022

Contact Information

1551 BISHOP ST STE 203
SAN LUIS OBISPO, CA
ZIP 93401
Phone: (805) 434-5530
Fax: (805) 434-0023

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for KRISTI LEIGH FENTON AGACNP-BC, an active Acute Care specialist practicing in San Luis Obispo, CA. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 24 documented patient claims. Among these therapy options, the most frequently utilized medication is Diazepam, which accounts for 24 claims alone.

Medication Index

No matching medications currently found on file.

Diazepam

Generic Formulation: DiazepamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 24
CA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.9
Peer Average Days Supply665
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$0.58

State Avg Cost Per Claim

$8.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.

Therapeutic Applications

This medication is used to treat episodes of increased seizures (such as cluster or breakthrough seizures) in people who are already taking medications to control their seizures. This product is only recommended for short-term treatment of seizure attacks. It is not for ongoing daily use to prevent seizures. Uncontrolled seizures can turn into serious (possibly fatal) seizures that do not stop (status epilepticus). This medication is not recommended for children younger than 6 months of age because of the risk of serious side effects. Diazepam works by calming the brain and nerves. It belongs to a class of drugs known as benzodiazepines.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like KRISTI LEIGH FENTON AGACNP-BC provides transparency into local medical care patterns within San Luis Obispo, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Acute Care** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.